5PSQ-028 The governance of PCSK9-inhibitors for the treatment of primary hypercholesterolaemia: appropriateness analysis

BackgroundRecently the European Medicines Agency approved Alirocumab and Evolocumab, two monoclonal antibodies against PCSK9 (PCSK9-inhibitors), a key protein in LDL-receptor degradation. These drugs, as monotherapy or in combination with other lipid-lowering agents, represent an important therapeut...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A214-A214
Hauptverfasser:	Garreffa, MR, Zito, C, Esposito, S, Monopoli, C, Naturale, MD, de Francesco, AE
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!